Results 111 to 120 of about 139,634 (224)
Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
PROTEOMICS, EarlyView.
Paul Perco +7 more
wiley +1 more source
Allergy, EarlyView.Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller +13 more
wiley +1 more source
Toxicological analyses of the bone matrix: Successes and challenges
Archaeometry, EarlyView.Abstract This study aimed to conduct an in‐depth and systematic literature review dealing with toxicological analyses on human bone tissue and focusing on the forensic toxicological and archaeotoxicological field. Several studies have focused their research on medical drugs, drugs of abuse, and trace elements on both human cadavers and skeletal remains,
Gaia Giordano +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1132-1156, April 2025.Abstract Structured medication reviews (SMRs) were introduced into the National Health Service (NHS) Primary Care to support the delivery of the NHS Long‐Term Plan for medicines optimization. SMRs improve the quality of care, reduce harm and offer value for money. However, evidence to support SMRs for patients with chronic kidney disease (CKD) stage G4‐
Cathy Margaret Pogson +3 more
wiley +1 more source
Risk of bias tools for medication adherence research: RoBIAS and RoBOAS
British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1457-1478, May 2025.Abstract Aims An unbiased means of documenting medication‐taking is important to ensure quality evidence about adherence research and to accurately identify individuals at risk of suboptimal adherence for the development of targeted and effective interventions.
Klarissa A. Sinnappah +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.▪ Background and Purpose NLRP3 is up‐regulated in inflammatory and autoimmune diseases. The development of NLRP3 inhibitors is challenged by the identification of compounds with distinct mechanisms of action avoiding side effects and toxicity. Triptolide is a natural product with multiple anti‐inflammatory activities, but a narrow therapeutic window ...
Mo‐Yu Ding +5 more
wiley +1 more source
Clinical &Experimental Allergy, EarlyView.ABSTRACT Background Chronic urticaria (CU) treatment with omalizumab is considered safe in short‐term studies. Large real‐world studies focusing on the long‐term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab‐treated CU patients in a large long‐term daily practice ...
Reineke Soegiharto +27 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2540-2551, May 2025.Abstract Aim To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. Materials and Methods In STEP 7 (NCT04251156), a double‐blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 ...
Weijun Gu +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S2, Page 3-19, April 2025.Abstract Obesity is a highly prevalent chronic multisystem disease associated with shortened life expectancy due to a number of adverse health outcomes. Epidemiological data link body weight and parameters of central fat distribution to an increasing risk for type 2 diabetes, hypertension, fatty liver diseases, cardiovascular diseases including ...
Matthias Blüher
wiley +1 more source
Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. [PDF]
Rheumatology (Oxford)Troum OM +4 more
europepmc +1 more source